After a quick FDA approval in a subset of endometrial cancer, GSK is back with more data for two Jemperli regimens in hopes of reaching a broader patient population. And AstraZeneca, utilizing a ...

On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a ...

Recent performance and why GSK stock is back on radar GSK (LSE:GSK) has quietly delivered a strong run this year, with the share price up about 34% year to date and roughly 44% over the past year, ...

GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over ...

(Reuters) – Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline’s consumer healthcare assets was rejected — should it raise the bid and risk overpaying or seek ...

GSK committed $270 million up front in recent months to gain access to early-stage assets in the class of cancer therapies known as antibody drug conjugates, or ADCs. The deals are part of a broad ...

A Reuters report regarding the rejection of Unilever's $68 billion offer for GlaxoSmithKline’s consumer healthcare assets is raising questions, including whether Unilever should raise the bid and risk ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...

A debate has broken out over whether Pfizer should have told pregnant women taking part in its maternal respiratory syncytial virus (RSV) vaccine trial that a trial of a similar GSK vaccine was ...

AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth ...